Business
SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations
LTR Pharma Limited (ASX:LTP) ("LTR Pharma" or "the Company") reports interim Phase II pharmacokinetic (PK) and safety data for SPONTAN®, demonstrating a rapid time to peak concentration (median Tmax 10 minutes) and a consistent safety profile, with no serious or severe treatment-emergent adverse events observed. The data support the Company's planned FDA 505(b)(2) regulatory pathway, subject to completion of final statistical analysis.
About this update from Ltr Pharma Limited
[{"type":"text","content":"Highlights","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Median Tmax of 10 minutes for SPONTAN® (5 mg) versus 60 minutes for oral vardenafil (20mg), consistent with Phase I study.","length":122,"tagName":"p"}]},{"val":[{"type":"text","content":"Interim data provide the key pharmacokinetic dataset requested by the FDA, including rapid absorption, repeat-dose profile, with no drug accumulation observed, and consistent pharmacokinetics across adult and geriatric populations.","length":231,"tagName":"p"}]},{"val":[{"type":"text","content":"Pharmacokinetic profile in subjects ≥65 years comparable to adults in the dataset, addressing a key FDA Pre-IND requirement.","length":124,"tagName":"p"}]},{"val":[{"type":"text","content":"Consistent safety profile observed, with no serious adverse events, no Grade 3 or 4 treatment-emergent adverse events, and no treatment-related discontinuations.","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"No drug accumulation observed following five days of repeat intranasal dosing (5 mg).","length":85,"tagName":"p"}]},{"val":[{"type":"text","content":"Interim data are expected to inform the Company's planned FDA 505(b)(2) regulatory pathway.","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"Final results, including full statistical analysis, expected Q3 CY2026.","length":71,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":889,"olType":false},{"type":"text","content":"SYDNEY, May 4, 2026 /PRNewswire/ -- LTR Pharma Limited (ASX:LTP) ("LTR Pharma" or "the Company") reports interim Phase II pharmacokinetic (PK) and safety data for SPONTAN®, demonstrating a rapid time to peak concentration (median Tmax 10 minutes) and a consistent safety profile, with no serious or severe treatment-emergent adverse events observed. The data support the Company's planned FDA 505(b)(2) regulatory pathway, subject to completion of final statistical analysis.","length":499,"tagName":"p"},{"type":"text","content":"These results indicate a pharmacokinetic profile distinct from oral PDE5 inhibitors, consistent with rapid-onset, on-demand use.","length":128,"tagName":"p"},{"type":"text","content":"The interim results indicate that the Study has characterised the key pharmacokinetic parameters requested by the FDA, including ...